Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041699 · ClinicalTrials.gov registry record · Phase 1
PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel
A Phase 1 study of Pharmacokinetics and Bleeding, sponsored by International Partnership for Microbicides.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT05041699 is a Phase 1 study of Pharmacokinetics and Bleeding that has completed, run by International Partnership for Microbicides. The registered enrollment target is 40 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05041699, a Phase 1 study of Pharmacokinetics and Bleeding, has completed, sponsored by International Partnership for Microbicides.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
A double-blind, randomized trial (1:1) to characterize the local and systemic pharmacokinetics (PK) of two DPV-LNG vaginal ring formulations
Conditions Studied
Interventions
- COMBINATION_PRODUCT IPM Ring-105
- COMBINATION_PRODUCT IPM Ring-106
Study Locations (2)
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- UPMC Magee-Womens Hospital, Center for Family Planning Research - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05041699
The ClinicalTrials.gov registry entry for NCT05041699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (34% lower). The listed sponsor is International Partnership for Microbicides, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which IPM Ring-105 is the first listed.
NCT05041699 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05041699 about?
NCT05041699 is a clinical study titled "PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel". A double-blind, randomized trial (1:1) to characterize the local and systemic pharmacokinetics (PK) of two DPV-LNG vaginal ring formulations
What is the current status of trial NCT05041699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-06-20. Estimated completion is 2024-10-07.
What conditions does trial NCT05041699 study?
This clinical trial studies the following conditions: Pharmacokinetics, Bleeding, Safety Issues.
What interventions are being tested in trial NCT05041699?
The interventions under investigation include: IPM Ring-105 (COMBINATION_PRODUCT), IPM Ring-106 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05041699?
This trial is sponsored by International Partnership for Microbicides, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05041699 being conducted?
This trial has 2 study locations across Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.